Veterinary Pharmaceuticals Market by Products, Animal Type, Mode of Administration, Indications, Distribution Channel, End User

List of Tables

The Veterinary Pharmaceuticals Market was valued at USD 37.46 billion in 2023 and is projected to grow to USD 40.53 billion in 2024, with a CAGR of 8.35%, reaching USD 65.71 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023]	USD 37.46 billion
Estimated Year [2024]	USD 40.53 billion
Forecast Year [2030]	USD 65.71 billion
CAGR (%)	8.35%

The veterinary pharmaceuticals market stands at the crossroads of innovation and traditional practices, blending decades of established research with breakthrough scientific advancements. In a rapidly changing ecosystem where the health and welfare of animals are paramount, the industry is being reshaped by new technologies, evolving regulatory environments, and shifting consumer demands. This introductory segment provides a panoramic view of current market trends, setting the stage for a detailed exploration of transformative shifts, segmentation nuances, regional distinctions, and leading companies.

Over the past few years, comprehensive research has highlighted the pivotal role that veterinary pharmaceuticals play in ensuring the wellbeing of domesticated and livestock animals alike. As stakeholders from farm owners to pet enthusiasts demand greater efficacy and safety, the market has responded by investing in innovative treatments and addressing unmet needs in animal health. By understanding the market dynamics at play, decision-makers are better positioned to navigate this complex landscape.

This analysis provides in-depth insights supported by solid data and valuable trend indicators, illustrating a future that is both challenging and ripe with opportunities. Such insights are crucial for organizations looking to remain competitive and responsive to the demands of a dynamic industry landscape. Prepared with an analytical lens, the content that follows bridges the gap between scientific research and business strategy, ensuring that expert opinions and actionable strategies guide the reader's understanding of the market.

Transformative Shifts Revolutionizing the Veterinary Pharmaceuticals Landscape

Recent years have witnessed transformative shifts that continue to redefine the veterinary pharmaceuticals industry. At the core of these shifts is an interplay between technological advancements, regulatory transformations, and evolving customer expectations. The integration of digital technologies into drug development processes, smart diagnostics tools, and data-driven treatment methodologies has catalyzed change across the value chain.

One of the most significant drivers of transformation lies in the incorporation of precision medicine and biotechnological tools. Innovations in genetic mapping and diagnostic testing have enabled more targeted interventions in animal health, allowing veterinarians to prescribe treatments that cater more precisely to individual animals' needs. This shift is being further bolstered by the adoption of automation and artificial intelligence, streamlining processes in both research and clinical practice. The result is an ecosystem where decision-making is not solely dependent on historical data but is continuously enhanced by real-time inputs and digital tools.

Regulatory bodies have also played a critical role in shaping industry dynamics. Updated guidelines and evolving standards have pushed companies to adhere to stricter quality controls, thereby ensuring safer and more effective products on the market. This regulatory evolution is complemented by increased partnership opportunities between academia and the private sector, fostering an environment of collaborative innovation.

The transformation is not only technological but also cultural. There is a growing recognition of the importance of sustainable practices and ethical considerations in animal treatment protocols. As market participants strive for improved transparency and accountability, there is a natural alignment towards research that emphasizes both animal welfare and product performance. This dual focus is setting new benchmarks and redefining what success looks like in an increasingly competitive market.

Throughout this period of rapid change, the industry has also had to adapt to external pressures, including economic fluctuations, global health crises, and altered consumer spending habits. Although these factors present challenges, they also serve as catalysts for interior change. Market players have responded by revisiting and revamping business models, operational efficiencies, and innovation strategies to stay ahead of the curve in a redefined market landscape.

Key Segmentation Insights Shaping Market Strategy

A close examination of market segmentation provides a deeper understanding of the diverse avenues through which veterinary pharmaceuticals operate. The product-based segmentation divides the market into drugs, medicinal feed, and vaccines, with each category offering further granularity. Drugs are analyzed based on subcategories such as analgesics, anti-infectives, anti-inflammatories, and parasiticides. Within these, anti-infectives are further broken down to highlight antibiotics and antifungals, while anti-inflammatories are classified as non-steroidal or steroidal in nature. Parasiticides continue to evolve with a focus on both ectoparasiticides and endoparasiticides, offering specialized treatments that target various parasitic threats.

The medicinal feed segment itself incorporates multiple dimensions. By reviewing products such as antibiotic medicated feed, antiparasitic medicated feed, growth promoters, nutritional medicated feed, and formulations that combine probiotics and prebiotics, the analysis underscores the multifaceted nature of modern animal nutrition. Vaccines rounded out by their own line of inquiry, are assessed in terms of inactivated and live formulations, reflecting advancements in immunization strategies that are efficiently tailored to specific animal illnesses.

Animal type segmentation brings another layer of insight, categorizing the market into segments that revolve around companion animals and livestock animals. The companion animal segment is further divided through studies focusing on cats, dogs, and horses, each of which presents unique health challenges and market requirements. Meanwhile, the livestock category covers cattle, poultry, sheep and goats, and swine, each managed under distinct husbandry practices and risk profiles.

Furthermore, the mode of administration, another critical segmentation, reveals significant shifts in treatment protocols. In this segment, injectable formulations are dissected into intramuscular and subcutaneous applications; oral formulations encompass capsules, liquid suspensions and syrups, as well as tablets; while topical treatments demonstrate their value through creams, lotions, and ointments. These investigations highlight user preferences, cost-effectiveness, and the nuances in therapeutic delivery.

The segmentation based on indications delves into the specific health needs of animals, addressing areas including chronic and acute pain management, immunological conditions, infectious diseases, metabolic disorders, neurological conditions, orthopedic issues, parasitic infections, and reproductive health concerns. This category is pivotal in aligning therapeutic developments with clinical necessities.

Additional segmentation dimensions include the distribution channel, which is reviewed by examining the roles of online pharmacies, retail pharmacies, and veterinary clinics. Similarly, an analysis of the end user category distinguishes among animal farms, pet owners, and veterinary hospitals. These comprehensive insights provide decision-makers with a multidimensional view of the market, ensuring that strategies are finely attuned to the specific needs and expectations of diverse stakeholders.

The integrated approach to segmentation not only clarifies market composition but also enables the identification of emerging trends and niche opportunities. It facilitates comparative analysis and strategic prioritization, ensuring that each segment is treated as a critical element in the broader market ecosystem. The granular understanding of each segment paves the way for tailored strategies that can drive both market penetration and sustained growth.

Based on Products, market is studied across Drugs, Medicinal Feed, and Vaccines. The Drugs is further studied across Analgesics, Anti-Infectives, Anti-Inflammatories, and Parasiticides. The Anti-Infectives is further studied across Antibiotics and Antifungals. The Anti-Inflammatories is further studied across Non-Steroidal and Steroidal. The Parasiticides is further studied across Ectoparasiticides and Endoparasiticides. The Medicinal Feed is further studied across Antibiotic Medicated Feed, Antiparasitic Medicated Feed, Growth Promoters, Nutritional Medicated Feed, and Probiotic & Prebiotic Medicated Feed. The Vaccines is further studied across Inactivated Vaccines and Live Vaccines.

Based on Animal Type, market is studied across Companion Animals and Livestock Animals. The Companion Animals is further studied across Cats, Dogs, and Horses. The Livestock Animals is further studied across Cattle, Poultry, Sheep & Goats, and Swine.

Based on Mode of Administration, market is studied across Injectable, Oral, and Topical. The Injectable is further studied across Intramuscular and Subcutaneous. The Oral is further studied across Capsules, Liquid Suspension & Syrup, and Tablets. The Topical is further studied across Creams, Lotions, and Ointments.

Based on Indications, market is studied across Chronic & Acute Pain Management, Immunological Conditions, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Orthopedic Disorders, Parasitic Infections, and Reproductive Health.

Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics.

Based on End User, market is studied across Animal Farms, Pet Owners, and Veterinary Hospitals.

Regional Insights Across Global Markets

A detailed examination of regional insights reveals synonymous trends across a spectrum of geographies that include the Americas, Europe, Middle East & Africa, and the Asia-Pacific region. The Americas emerge as a key market driven by comprehensive healthcare regulations and high levels of research and development activity, setting an example in integrated veterinary health solutions. This region showcases advanced adoption of technological innovations and a robust network of industry stakeholders.

In addition, the combined region of Europe, Middle East & Africa offers a dynamic market environment where regulatory rigor coexists with growing emphasis on animal welfare. The diversity of this region is marked by innovations in product formulations as well as adaptive strategies to meet varied regional requirements. This area benefits from both the scientific advancements emanating from Europe and the emerging opportunities in developing economies within the Middle East and Africa, thereby creating a rich tapestry of challenges and opportunities for businesses operating within this sphere.

The Asia-Pacific region presents a unique market scenario characterized by growth potential, driven by rising disposable incomes and heightened awareness regarding animal health. Investments in research and a surge in demand for advanced pharmaceuticals have stimulated market activity in this region. Here, a strong emphasis on local manufacturing and cost-effective treatment protocols has resulted in competitive product offerings that continue to drive market expansion.

Each region encapsulates distinct regulatory, economic, and cultural influences, underlining the need for a tailored approach to market strategy. Strategic investments and region-specific partnerships further enhance the potential to achieve market penetration, underscoring the importance of regional perspectives in a globally interconnected industry landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Key Industry Players Driving the Market

The competitive landscape within the veterinary pharmaceuticals market is both diverse and dynamic, with several leading companies establishing a significant market presence. Industry giants such as Aurora Pharmaceutical, Inc. and Biogenesis Bago S.A. have been at the forefront of innovation, while Biovac Ltd. and Boehringer Ingelheim International GmbH continue to leverage their expansive resources to influence market trends. Ceva Sante Animale and Chanelle Pharma add to the competitive mix, pushing boundaries through strategic innovations and product line expansions.

China Animal Husbandry Industry Co., Ltd. and Dechra Pharmaceuticals PLC have also carved out a niche by closely aligning their operations with the latest research and technology integrations, enhancing product efficacy. ECO Animal Health Group PLC, Elanco Animal Health Incorporated, and Heska Corporation further enrich this diverse landscape by pioneering sustainable and cost-effective solutions.

Not to be overlooked, Hester Biosciences Limited, Indian Immunologicals Ltd., and Intas Pharmaceuticals Ltd. leverage deep local insights and scientific acumen to serve niche market segments. The involvement of Laboratorio Drag Pharma Chile Invetec S.A. alongside global leaders like Merck & Co., Inc. emphasizes the growing importance of multinational collaborations in this industry. Neogen Corporation, Norbrook Group, Phibro Animal Health Corporation, and Teknofarma S.r.l. provide additional layers of expertise, shaping both product development and market strategy through consistent innovation and research-driven methodologies.

Other prominent players including Vetoquinol Group, Vetpharma Animal Health S.L. by Insud Pharma S.L.U., Virbac S.A., Zendal Group, and Zoetis Inc. serve as key contributors to the market's evolving landscape. Their ongoing investments in research and cross-continental partnerships are central to driving industry progress and addressing emerging challenges. The wide-ranging expertise, from biotechnological advancements to comprehensive distribution networks, encapsulates the multi-dimensional approach that these companies bring to critical market segments.

The report delves into recent significant developments in the Veterinary Pharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Aurora Pharmaceutical, Inc., Biogenesis Bago S.A., Biovac Ltd., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Chanelle Pharma, China Animal Husbandry Industry Co., Ltd., Dechra Pharmaceuticals PLC, ECO Animal Health Group PLC, Elanco Animal Health Incorporated, Heska Corporation, Hester Biosciences Limited, Indian Immunologicals Ltd., Intas Pharmaceuticals Ltd., Laboratorio Drag Pharma Chile Invetec S.A., Merck & Co., Inc., Neogen Corporation, Norbrook Group, Phibro Animal Health Corporation, Teknofarma S.r.l., Vetoquinol Group, Vetpharma Animal Health S.L. by Insud Pharma S.L.U., Virbac S.A., Zendal Group, and Zoetis Inc.. Actionable Recommendations for Strategic Industry Advancement

In an industry marked by rapid transformative change, industry leaders must align their strategic objectives with innovative practices and forward-thinking policies. The actionable recommendations outlined here are intended to propel growth, enhance operational efficiencies, and secure a competitive advantage in the veterinary pharmaceuticals market.

First, prioritizing research and development is critical. Embracing emerging technologies such as artificial intelligence and precision medicine can enable companies to create more targeted and effective therapeutic solutions. Collaborative efforts with academic institutions and research centers can further catalyze innovation, ensuring that product pipelines reflect both current needs and future trends. Leveraging digital transformation to enhance data analytics and clinical trial management is a powerful catalyst for achieving breakthrough treatments.

Furthermore, diversifying product portfolios represents an indispensable strategy. By expanding into various subsegments-ranging from drugs and medicinal feed to vaccines-companies can mitigate risk while tapping into niche markets. Strategic investments in the development of advanced formulations, such as biotechnologically enhanced vaccines and targeted anti-inflectives, would not only broaden market reach but also improve overall treatment efficacies. Understanding the complex segmentation based on animal type, mode of administration, and specific disease indications will allow for the development of purpose-driven solutions that cater to a broad spectrum of needs.

A second recommendation centers on optimizing distribution channels. In a market where channel efficiency directly influences accessibility and sales performance, companies are advised to bolster partnerships with both traditional outlets and emerging digital platforms. Enhancements in online pharmacies, retail partnerships, and veterinary clinic networks can streamline product availability and improve customer engagement. Mapping out supply chain efficiencies and integrating robust logistics systems will prove beneficial in reducing lead times and enhancing service quality.

Third, fostering strategic alliances remains a potent avenue for sustained growth. Forming robust alliances with local and international partners can facilitate knowledge transfer, expedite market entry, and offer avenues for joint research initiatives. For instance, aligning with regional distributors and local players in high-growth markets, such as those found in the Asia-Pacific and Europe, Middle East & Africa, can offer unique market insights and accelerate penetration strategies.

Lastly, maintaining an agile mindset in the face of regulatory and market changes is non-negotiable. In a landscape heavily shaped by evolving standards and consumer expectations, organizations must commit to continually updating their operational protocols and compliance measures. This dynamic approach can safeguard against emerging risks and ensure that companies remain ahead of regulatory shifts. By continuously monitoring market trends and integrating adaptive strategies, industry leaders can navigate uncertainties while capitalizing on new opportunities.

The above recommendations are designed to guide strategic decision-making, ensuring that companies do not merely react to industry changes but actively shape the future of veterinary pharmaceuticals. A balanced focus on research, technological innovation, product diversification, channel optimization, and strategic partnerships will pave the way for sustained market leadership.

Conclusion: Navigating the Future with Informed Strategies

In summary, the evolving landscape of the veterinary pharmaceuticals market is characterized by an interplay of innovation, rigorous research, and adaptive business strategies. This comprehensive analysis has underscored the significance of in-depth segmentation, revealing the nuanced differences in product categories, animal types, modes of administration, indications, distribution channels, and end users. These segmentation insights empower decision-makers with the groundwork needed to tailor strategies that can effectively navigate both macro and micro level market trends.

Furthermore, regional insights have highlighted that distinct geographies such as the Americas, Europe, Middle East & Africa, and Asia-Pacific each offer unique opportunities and challenges. Whether driving innovation in technologically advanced regions or tapping into the growth potential of developing markets, organizations must adopt a flexible and localized strategy. The global perspective reinforces that strategic agility and regional specificity are crucial to maintaining competitiveness in a dynamic environment.

The competitive analysis provided a snapshot of key industry players, illustrating the diverse approaches they employ to remain at the forefront of innovation. From multinational conglomerates to emerging local enterprises, the collective efforts in research and development, product diversification, and strategic alliances are reshaping market dynamics. This convergence of expertise and market presence demonstrates that sustained success is a result of both rigorous planning and adaptive practices.

As we look to the future, the veterinary pharmaceuticals market is poised to benefit from continuous technological advancements and a deeper understanding of consumer needs. The integration of cutting-edge research with market-driven strategies is leading the way towards a new era of innovation in animal healthcare. Ultimately, the road ahead is defined by informed decision-making, strategic foresight, and a relentless commitment to excellence in every facet of business operations.

Product Code: MRR-032F197B035E

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing incidence of diseases in livestock and companion animals, rising need for treatment and medications
  - 5.1.1.2. Increase in R&D activities for veterinary healthcare
- 5.1.2. Restraints
  - 5.1.2.1. Risk of recalls associated with veterinary drugs and vaccines
- 5.1.3. Opportunities
  - 5.1.3.1. Development of new and advanced veterinary pharmaceuticals
  - 5.1.3.2. Increasing investment by companies for the expansion of veterinary vaccine facilities
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with the adverse effects of veterinary vaccine
5.2. Market Segmentation Analysis
- 5.2.1. Products: The growing demand for medicinal feed to improve animal health and productivity
- 5.2.2. Animal Type: Growing need for veterinary pharmaceuticals in livestock animals owing to disease control and productivity enhancement
- 5.2.3. Mode of Administration: Increasing utilization of capsules for ensuring dosage accuracy
- 5.2.4. Indications: Emerging focus on the introduction of drugs advancing treatments for metabolic disorders
- 5.2.5. Distribution Channel: Growing consumer preference for online pharmacies owing to their convenience and wide range of products
- 5.2.6. End User: Expanding applications of veterinary pharmaceuticals by pet owners
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Veterinary Pharmaceuticals Market, by Products

6.1. Introduction
6.2. Drugs
- 6.2.1. Analgesics
- 6.2.2. Anti-Infectives
  - 6.2.2.1. Antibiotics
  - 6.2.2.2. Antifungals
- 6.2.3. Anti-Inflammatories
  - 6.2.3.1. Non-Steroidal
  - 6.2.3.2. Steroidal
- 6.2.4. Parasiticides
  - 6.2.4.1. Ectoparasiticides
  - 6.2.4.2. Endoparasiticides
6.3. Medicinal Feed
- 6.3.1. Antibiotic Medicated Feed
- 6.3.2. Antiparasitic Medicated Feed
- 6.3.3. Growth Promoters
- 6.3.4. Nutritional Medicated Feed
- 6.3.5. Probiotic & Prebiotic Medicated Feed
6.4. Vaccines
- 6.4.1. Inactivated Vaccines
- 6.4.2. Live Vaccines

7. Veterinary Pharmaceuticals Market, by Animal Type

7.1. Introduction
7.2. Companion Animals
- 7.2.1. Cats
- 7.2.2. Dogs
- 7.2.3. Horses
7.3. Livestock Animals
- 7.3.1. Cattle
- 7.3.2. Poultry
- 7.3.3. Sheep & Goats
- 7.3.4. Swine

8. Veterinary Pharmaceuticals Market, by Mode of Administration

8.1. Introduction
8.2. Injectable
- 8.2.1. Intramuscular
- 8.2.2. Subcutaneous
8.3. Oral
- 8.3.1. Capsules
- 8.3.2. Liquid Suspension & Syrup
- 8.3.3. Tablets
8.4. Topical
- 8.4.1. Creams
- 8.4.2. Lotions
- 8.4.3. Ointments

9. Veterinary Pharmaceuticals Market, by Indications

9.1. Introduction
9.2. Chronic & Acute Pain Management
9.3. Immunological Conditions
9.4. Infectious Diseases
9.5. Metabolic Disorders
9.6. Neurological Disorders
9.7. Orthopedic Disorders
9.8. Parasitic Infections
9.9. Reproductive Health

10. Veterinary Pharmaceuticals Market, by Distribution Channel

10.1. Introduction
10.2. Online Pharmacies
10.3. Retail Pharmacies
10.4. Veterinary Clinics

11. Veterinary Pharmaceuticals Market, by End User

11.1. Introduction
11.2. Animal Farms
11.3. Pet Owners
11.4. Veterinary Hospitals

12. Americas Veterinary Pharmaceuticals Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Veterinary Pharmaceuticals Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Veterinary Pharmaceuticals Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. Dechra Pharmaceuticals to acquire Invetx to enhance veterinary therapeutics portfolio
- 15.3.2. TechInvention and Botswana Institute partner to revolutionize veterinary vaccine production
- 15.3.3. Merck Animal Health introduces innovative RNA-particle Canine Flu vaccine
- 15.3.4. Huvepharma Expands with EUR 72 million veterinary vaccine plant to boost global supply and innovation
- 15.3.5. Virbac strengthens position in Japanese market with Sasaeah acquisition
- 15.3.6. FDA approvals enhance veterinary treatments for heart and respiratory conditions
- 15.3.7. Impact of EVML on global veterinary medicine accessibility and AMR mitigation
- 15.3.8. Zendal and CSIC unveil innovative Neoleish vaccine to combat canine leishmaniasis
- 15.3.9. Merck Animal Health acquires Elanco's aqua business to strengthen aquaculture presence
- 15.3.10. Huateng Pharma expands with fluralaner and sarolaner launch, revolutionizing veterinary pharmaceuticals
- 15.3.11. ENTOD Pharmaceuticals expands into veterinary market with "FUR by ENTOD" division
- 15.3.12. Indian Immunologicals Ltd (IIL) invests INR 700 crore in Hyderabad vaccine plant to boost livestock disease eradication
- 15.3.13. Virbac acquires stake in Globion to boost avian vaccine market presence in India
- 15.3.14. Strategic collaboration between Pirbright Institute and USask's VIDO to boost vaccine innovation and pandemic readiness
15.4. Strategy Analysis & Recommendation
- 15.4.1. Dechra Pharmaceuticals PLC
- 15.4.2. Zoetis Inc.
- 15.4.3. Ceva Sante Animale
- 15.4.4. Boehringer Ingelheim GmbH

Companies Mentioned

1. Aurora Pharmaceutical, Inc.
2. Biogenesis Bago S.A.
3. Biovac Ltd.
4. Boehringer Ingelheim International GmbH
5. Ceva Sante Animale
6. Chanelle Pharma
7. China Animal Husbandry Industry Co., Ltd.
8. Dechra Pharmaceuticals PLC
9. ECO Animal Health Group PLC
10. Elanco Animal Health Incorporated
11. Heska Corporation
12. Hester Biosciences Limited
13. Indian Immunologicals Ltd.
14. Intas Pharmaceuticals Ltd.
15. Laboratorio Drag Pharma Chile Invetec S.A.
16. Merck & Co., Inc.
17. Neogen Corporation
18. Norbrook Group
19. Phibro Animal Health Corporation
20. Teknofarma S.r.l.
21. Vetoquinol Group
22. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
23. Virbac S.A.
24. Zendal Group
25. Zoetis Inc.